PTGS2 and neoplasm: Tumor-derived prostaglandins have previously been reported to prevent the accumulation of CD103+ DCs into the TME (37); however, we did not observe increased CD103+ DCs in Ptgs2−/− tumors (Supplementary Fig. S6D).